OmniAb
Update in progressOABI (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
OmniAb, Inc. licenses discovery research technology to pharma, biotech companies and academic institutions to accelerate therapeutics worldwide. Its platform builds and screens diverse antibody repertoires to identify optimal antibodies and other binding proteins. Biological Intelligence powers engineered transgenic animals (OmniRat, OmniChicken, OmniMouse) to generate human-sequence antibodies, plus bispecifics (OmniFlic, OmniClic), OmniTaur, OmnidAb, and OmniDeep AI tools. Founded 2012, Emeryville, CA.
Company score
- Sentiment
- 0.46
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.09
- Governance
- 0.03
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.03
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.25
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!